Formulations of hormone therapy and risk of Parkinson's disease.
about
Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain DiseasesEtiologic Framework for the Study of Neurodegenerative Disorders as Well as Vascular and Metabolic Comorbidities on the Grounds of Shared Epidemiologic and Biologic FeaturesLifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.
P2860
Formulations of hormone therapy and risk of Parkinson's disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Formulations of hormone therapy and risk of Parkinson's disease.
@ast
Formulations of hormone therapy and risk of Parkinson's disease.
@en
Formulations of hormone therapy and risk of Parkinson's disease.
@nl
type
label
Formulations of hormone therapy and risk of Parkinson's disease.
@ast
Formulations of hormone therapy and risk of Parkinson's disease.
@en
Formulations of hormone therapy and risk of Parkinson's disease.
@nl
prefLabel
Formulations of hormone therapy and risk of Parkinson's disease.
@ast
Formulations of hormone therapy and risk of Parkinson's disease.
@en
Formulations of hormone therapy and risk of Parkinson's disease.
@nl
P2093
P2860
P356
P1433
P1476
Formulations of hormone therapy and risk of Parkinson's disease.
@en
P2093
Andrea Z LaCroix
Brad A Racette
Gary M Franklin
Harvey Checkoway
Jessica I Lundin
Phillip D Swanson
Terri Smith-Weller
Thanh G N Ton
W T Longstreth
P2860
P304
P356
10.1002/MDS.26037
P407
P577
2014-09-25T00:00:00Z